Clinical study on cholesterol-lowering effect of RYR Cholestin among Americans with moderate hy-percholesterolemia
- VernacularTitle:红曲对中度血脂升高美国人调节血脂作用的临床研究
- Author:
Ji-Hong LU
1
;
Bonovich KERMIT
;
Colfer HARRY
;
Davidson MICHAEL
;
A.Dujo-Vne CARLOS
;
Fried L. DAVID
;
Greenspan MITCHELL
;
Karlsberg P. RONALD
;
King P. STEPHEN
;
LaForce F. CRAIG
;
Litt MARC
;
McGhee J.ROBERT
;
Run-Hai ZENG
;
Jia-Shi ZHU
;
Ning-Zhi TAN
Author Information
1. 华茂北京临床药理研究中心
- Keywords:
Monascus purpureus (Red Yeast) rice (RYR Cholestin);
Hyperlipidemia;
LDL-Cho-lesterol;
Triglycerides;
HDL-Cholesterol
- From:
Shanghai Journal of Preventive Medicine
2013;(9):501-506
- CountryChina
- Language:Chinese
-
Abstract:
[Objective] To evaluate lipid -lowering efficacy and safety of RYR Cholestin , or Monascus purpureus (Red Yeast) Rice, in Americans with moderate hypercholesterolemia. [Methods] This study was an open-label, self-control, and multi-center clinical trial.A total of 187 subjects were entered into this trial (serum LDL-Cholesterol 3.50~4.92 mmol/L,total cholesterol 5.18~7.25 mmol/L, male:female=116∶71) , of whom 162 completed the study .Subjects were placed on the NCEP Step I Diet throughout the study and RYR Cholestin (2.4 g/day) was administered for 8 weeks following initial 4-week diet control . [ Results] Being on the diet alone for 4 weeks resulted in no significant changes in serum lipids .RYR Cholestin treatment for 8 weeks reduced serum total cholesterol , LDL-Cholesterol and triglycerides by 16 .6%, 24 .0%, and 25 .2%, respectively , and increased HDL-Cholesterol by 14 .3%( all P<0 .001 ) .There were 97 .5% of patients having ≥10% improvement in at least one of lipid risk factors, and 79.0%having ≥20% improvement.Discontinuation of RYR Cholestin intervention for 14 d led to a return of serum lipids to baseline of pre -study .And 29 possible product -related mild adverse re-actions were reported . [ Conclusion] RYR Cholestin is well tolerated and effective in reducing total and LDL-Cholesterol, and triglycerides, as well as in increasing HDL-Cholesterol in hypercholesterolemic patients, but those indicators return to the beginning baseline when the treatment is discontinued .
